Diadema Partners »

Mineralys Therapeutics shares owned by Diadema Partners

Quarter-by-quarter ownership of Mineralys Therapeutics (MLYS) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Mineralys Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Mineralys Therapeutics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Mineralys Therapeutics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $907k 25k 36.29

More positions owned by Diadema Partners

Viking Therapeutics (VKTX)
Vertex Pharmaceuticals Incorporated (VRTX)
Bridgebio Pharma (BBIO)
Spdr Series Trust State Street Spd Put Option (XBI)
Praxis Precision Medicines I Com New Put Option (PRAX)
Johnson & Johnson (JNJ)
Avidity Biosciences Ord Call Option (RNA)
Capricor Therapeutics Com New (CAPR)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Jazz Pharmaceuticals Shs Usd Call Option (JAZZ)
Terns Pharmaceuticals (TERN)
Apogee Therapeutics Call Option (APGE)
Structure Therapeutics Sponsored Ads Call Option (GPCR)
Regeneron Pharmaceuticals (REGN)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Diadema Partners

Top funds holding Mineralys Therapeutics

Catalys Pacific
RA Capital Management
Samsara BioCapital
Caligan Partners
BlackRock
Vanguard Group
State Street Corporation
Caption Management
Citadel Advisors
FMR
Franklin Resources
Laurion Capital Management
Boothbay Fund Management
Holocene Advisors
Sr One Capital Management

View all funds holding Mineralys Therapeutics